A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

February 1, 2021

Study Completion Date

February 15, 2021

Conditions
Essential Tremor
Interventions
DRUG

SAGE-324

SAGE-324 oral tablet

DRUG

SAGE-324 Placebo

SAGE-324 matched placebo oral tablet

Trial Locations (27)

10032

Sage Investigational Site, New York

23229

Sage Investigational Site, Richmond

25701

Sage Investigational Site, Huntington

28806

Sage Investigational Site, Asheville

30030

Sage Investigational Site, Decatur

31406

Sage Investigational Site, Savannah

32608

Sage Investigational Site, Gainesville

33024

Sage Investigational Site, Hollywood

33136

Sage Investigational Site, Miami

33176

Sage Investigational Site, Miami

33486

Sage Investigational Site, Boca Raton

33609

Sage Investigational Site, Tampa

33713

Sage Investigational Site, St. Petersburg

33980

Sage Investigational Site, Port Charlotte

45212

Sage Investigational Site, Cincinnati

45417

Sage Investigational Site, Dayton

48334

Sage Investigational Site, Farmington Hills

62702

Sage Investigational Site, Springfield

66160

Sage Investigational Site, Kansas City

72758

Sage Investigational Site, Rogers

74136

Sage Investigational Site, Tulsa

77030

Sage Investigational Site, Houston

80113

Sage Investigational Site, Englewood

85258

Sage Investigational Site, Phoenix

90806

Sage Investigational Site, Long Beach

93710

Sage Investigational Site, Fresno

99202

Sage Investigational Site, Spokane

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sage Therapeutics

INDUSTRY

NCT04305275 - A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor | Biotech Hunter | Biotech Hunter